This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.
12/22/14 11:36AM
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
12/22/14 6:14AM
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
12/19/14 4:16PM
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
12/19/14 9:02AM
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
12/19/14 8:25AM
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
12/18/14 10:01AM
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
12/17/14 9:20AM
Auspex is expected to seek U.S. approval for SD-809 next year.
12/16/14 4:06PM
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
12/16/14 11:20AM
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
12/15/14 11:49AM
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.
12/15/14 9:23AM
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
12/12/14 6:05AM
Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
12/10/14 9:21AM
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
12/8/14 5:45PM
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
12/8/14 7:15AM
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
12/7/14 5:28PM
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
12/7/14 3:33PM
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
12/7/14 12:30PM
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
12/6/14 1:00PM
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.
12/6/14 1:00PM
New Adcetris data are from a phase III study known AETHERA are being presented in full at the American Society of Hematology (ASH) annual meeting underway in San Francisco.
12/6/14 11:00AM
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
12/6/14 11:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
12/5/14 6:00AM
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.
12/3/14 4:01PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs